China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts

T2Covered by 1 source · first reported by China: SCMP Tech / TechNode / Pandaily / KrASIA / Sixth Tone at 26 Sept, 01:00 UTC

Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on…

science

Sources

• T2China’s biotech firms move up value chain as drug deals evolve beyond licensing: analystsChina: SCMP Tech / TechNode / Pandaily / KrASIA / Sixth Tone26 Sept, 01:00